OncLive TV

Anobel Odisho, MD, urologic oncology fellow, University of Washington, discusses the use of a risk prediction model for patients with renal cell carcinoma.

Cecile Pizot, biostatistician in epidemiology at the International Prevention Research Institute, discusses the changes in mortality rates in breast cancer around the world. In a study on 47 countries, 39 saw breast cancer mortality rates decline, but mortality rates were on the rise in Latin American and Asian countries.

Elizabeth A. Mittendorf, MD, PhD, associate professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the possibility of using vaccines as a preventative measure for breast cancer, particularly to fight recurrence.

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, discusses the mechanism of action of Yttrium-90 in the treatment of patients with liver-dominant, metastatic colorectal cancer.

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the search for actionable biomarkers in the treatment of patients with ovarian cancer.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the challenges associated with the patient demographics of cervical cancer.

Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses why the Syk inhibitor entospletinib demonstrates efficacy in patients with mantle cell lymphoma (MCL).

David Carbone, MD, PhD, director of the James Thoracic Center, and professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses the effectiveness of different therapies to treat patients with lung cancer.

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses what the future holds for the development of immunotherapy and targeted therapy in the treatment of patients with lung cancer.

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses combining cobimetinib and paclitaxel as a first-line treatment in patients with advanced triple-negative breast cancer.

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia who fail on ibrutinib or idelalisib.

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses the recent explosion of immunotherapy research in the treatment landscape of bladder cancer.

Mrinal Patnaik, MBBS, hematologist, Mayo Clinic, discusses the encouraging results seen in a phase II trial evaluating the activity of SL-401 in patients with advanced, high risk myeloproliferative neoplasms, including chronic myelomonocytic leukemia.

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses ways to manage patients with melanoma who may experience adverse events in response to treatment with immunotherapy.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the history of bortezomib as a treatment for patients with mantle cell lymphoma.

Omid A. Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses how to accurately select patients who are likely to have durable and long responses with single-agent immunotherapy versus combination treatment.

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a with hydroxyurea in the treatment of patients with high risk polycythemia vera and essential thrombocythemia.

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses immunotherapy combinations in melanoma.

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at Memorial Sloan Kettering Cancer Center, 2014 Giant of Cancer Care in Melanoma, discusses an ongoing clinical trial that will explore optimal treatments for patients with melanoma who fail on a PD-1 inhibitor as a single agent.

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses patient preferences for cervical cancer treatment, as well as the demographics of this population.

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma.

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses research evaluating different immune checkpoint pathways in patients with acute myeloid leukemia.

Jason J. Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses ongoing studies exploring immunotherapy for the treatment of patients with melanoma.

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses current treatment approaches for patients with human pappillomavirus (HPV)-positive head and neck cancer, as well as potential changes for those regimens.

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses an ongoing study exploring the optimal sequence of immunotherapy agents and targeted therapies for patients with melanoma.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the rationale for investigating venetoclax as a treatment for patients with multiple myeloma.

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses a study exploring the various molecular characteristics of colorectal cancer (CRC) tumors.

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago Medicine, discusses how the presence or absence of CD8 T cells can affect treatment approaches for patients with melanoma.

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with colorectal cancer.